Peer-Reviewed Publication
Clin Transl Radiat Oncol2026;60101245.September 1, 2026Journal Article
Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study - Study protocol.
S Anderson1,2, M C Douglas3,4,2, R Valentine1, L Grocutt1, G J Inman5,2, L Hay1,2, S Wright3,2, K Mair6, C Kelly7, R Seddon7, A Shaw7, MacMillan A7, J Gourlay7, J Flach7, E Au7, C Vens8,2, C Schoenherr5,2, D Grose1, C Lamb1, S Schipani1, S Vohra1, C Wilson1, C Paterson1,2
1Beatson West of Scotland Cancer Centre, Glasgow.
2Glasgow Head & Neck cancer (GlaHNC) research group, CRUK RadNet Glasgow+, United Kingdom.
3Queen Elizabeth University Hospital, Glasgow.
4Glasgow Royal Infirmary, Glasgow.
5CRUK Scotland Institute, University of Glasgow, Glasgow.
6Patient and public involvement representative, United Kingdom.
7Glasgow Oncology Clinical Trials Unit, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
8School of Cancer Sciences, Wolfson Wohl cancer centre, University of Glasgow, Glasgow, United Kingdom.
Abstract
BACKGROUND: The incidence of head and neck squamous cell cancer (HNSCC), including HPV-positive and negative oropharyngeal squamous cell cancer (OPSCC) is rising. HPV-negative and some HPV-positive OPSCC has poor outcomes. Attempts to uniformly intensify treatment in poor-prognosis HNSCC populations have been unsuccessful. Diffusion-weighted MRI (DW-MRI) has been used during radiotherapy to identi…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans